Effect of Type 2 Diabetes Genetic Risk Information on Health Behaviors and Outcomes

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

450 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-04-30

Study Completion Date

2013-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of the study is to assess the clinical utility of a genetic test for Type 2 diabetes risk in combination with standardized risk assessment compared with standardized risk assessment alone, and to measure whether changes in perceived risk following genetic testing for Type 2 diabetes risk are correlated with behavior change and increased concern about risk for Type 2 diabetes.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Genetic Testing for Type 2 Diabetes

NCT01060540

Diabetes Mellitus

COMPLETED NA

Understanding of Genetic Risk Information for Type 2 Diabetes

NCT01186354

Diabetes Mellitus, Type 2

COMPLETED NA

GENErating Behavior Change, An Integrative Health Coaching and Genetic Risk Testing Pilot

NCT01766271

Coronary Heart Disease Risk

COMPLETED NA

Genetic Counseling and Lifestyle Change for Diabetes Prevention

NCT01034319

Pre-diabetes Overweight Metabolic Syndrome

UNKNOWN PHASE2

Lifestyle Intervention in Individuals With Low or High Genetic Risk for Type 2 Diabetes

NCT02709057

Type 2 Diabetes

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

One thousand outpatients will be enrolled over two years at two university-affiliated primary care clinics. Patients will be assigned to one of three study arms: those who want genetic testing for diabetes risk will be randomly assigned to either receive the testing in addition to the SRA (SRA+G) or to receive the SRA only (SRA-only). Those who do not wish to have genetic testing will receive the SRA only. All patients will be surveyed at baseline, immediately after going through the SRA (risk-counseling visit; 2-4 weeks after initial visit), at 3 months post risk counseling visit and at 12 months post risk counseling visit. BMI, waist circumference, fasting plasma glucose and insulin will be measured at baseline and 12 months. Surveys will allow us to track patients' emotional responses to diabetes risk information and changing perceptions of personal risk for Type 2 diabetes over time, and to see if these correlate with subsequent diet and exercise behaviors.

We will use a linear model to assess the effects of genetic testing among the three study groups, using HOmeostasis Model Assessment of Insulin Resistance (HOMA-IR) and weight loss as the primary outcomes. We will use generalized linear ordinal regression models to fit the ordinal survey outcomes of risk perceptions to the continuous HOMA-IR and weight outcome variables.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Mellitus, Type 2

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SRA+genetic test

patients randomized to receive genetic test for type 2 diabetes risk will be followed and surveyed and will be counseled based on SAR and genetic risk for type 2 diabetes

Group Type ACTIVE_COMPARATOR

Standardized Risk Assessment

Intervention Type OTHER

patients interested in genetic testing will be randomly assigned to either get testing for type 2 diabetes or not. All arms with receive standardized risk asessements. This study is evaluating behavior after receipt of genetic risk information and different types of counseling.

SRA only

Patients randomized to not get genetic testing will be followed and surveyed and will be counseled based on SRA only

Group Type NO_INTERVENTION

No interventions assigned to this group

no testing control

Patients not interested in genetic testing will be followed and surveyed. Counseling will be based on SRA only

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Standardized Risk Assessment

patients interested in genetic testing will be randomly assigned to either get testing for type 2 diabetes or not. All arms with receive standardized risk asessements. This study is evaluating behavior after receipt of genetic risk information and different types of counseling.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Are male or female outpatients
* No self-reported history of diabetes
* No self-reported history of prior genetic testing for diabetes
* Not pregnant (self report)
* Are ≥18 and \<81 years of age
* Scheduled to receive serum glucose test in participating clinic
* Fasting at time of blood draw (no food or drink - except water - previous 8 hours: self report)
* Able and willing to give legally effective consent
* Able and willing to participate in patient questionnaires
* Ambulatory

Exclusion Criteria

* Previously or currently taking medications for lowering glucose (i.e., exenatide, pramlintide, metformin, rosiglitazone, pioglitazone, or future diabetes drugs) based on self-report and/or prescreening
* Self-report of current or prior diabetes diagnosis
* Self-reported prior history of genetic testing for diabetes
* Baseline serum glucose test result \>125

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR